Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) have been assigned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $19.5714.

A number of analysts have recently weighed in on ADPT shares. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Morgan Stanley cut their target price on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. BTIG Research reiterated a “buy” rating and set a $22.00 target price on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. JPMorgan Chase & Co. cut their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th.

Adaptive Biotechnologies Price Performance

ADPT opened at $16.70 on Tuesday. The business has a fifty day simple moving average of $14.22 and a 200 day simple moving average of $15.65. The company has a market capitalization of $2.67 billion, a PE ratio of -50.61 and a beta of 2.16. Adaptive Biotechnologies has a 1 year low of $9.90 and a 1 year high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The firm’s quarterly revenue was up 35.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.20) EPS. Equities analysts anticipate that Adaptive Biotechnologies will post -0.48 earnings per share for the current fiscal year.

Insider Activity at Adaptive Biotechnologies

In other news, CEO Chad M. Robins sold 470,167 shares of the business’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total transaction of $6,192,099.39. Following the completion of the transaction, the chief executive officer owned 2,301,113 shares of the company’s stock, valued at approximately $30,305,658.21. The trade was a 16.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Harlan S. Robins sold 470,266 shares of the business’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total value of $6,193,403.22. Following the transaction, the insider directly owned 1,522,058 shares of the company’s stock, valued at $20,045,503.86. This trade represents a 23.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,771,436 shares of company stock worth $24,075,997 in the last three months. Insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Perceptive Advisors LLC acquired a new position in Adaptive Biotechnologies in the 1st quarter worth about $2,117,000. Bank of America Corp DE lifted its holdings in shares of Adaptive Biotechnologies by 52.3% during the first quarter. Bank of America Corp DE now owns 1,227,917 shares of the company’s stock worth $17,043,000 after purchasing an additional 421,645 shares during the period. Amundi acquired a new position in shares of Adaptive Biotechnologies during the first quarter worth $148,000. California State Teachers Retirement System lifted its holdings in shares of Adaptive Biotechnologies by 28.4% during the first quarter. California State Teachers Retirement System now owns 143,658 shares of the company’s stock worth $1,994,000 after purchasing an additional 31,782 shares during the period. Finally, SummitTX Capital L.P. acquired a new position in shares of Adaptive Biotechnologies during the first quarter worth $4,409,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.